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CD8+ T cells play a critical role in antitumor 
immune response. Killing of tumor cells by 
CTLs is triggered after interaction of TCR 
with the specifi  c tumor peptide–MHC-I com-
plex. The TCR and several coreceptors thus 
become localized at the T cell surface, leading 
to the formation of signal complexes with in-
tracellular molecules and the initiation of a 
transduction cascade, resulting in the execution 
of eff  ector functions. For CTLs, the major ef-
fector function is mediated through directional 
exocytosis of cytotoxic granules, primarily 
containing perforin and granzymes, into the 
target leading to cell death (1). It has been 
widely documented that after initial TCR-
  dependent stimulation, adhesion/costimulatory 
proteins are repositioned at the T cell–APC 
contact site, referred to as the immunological 
synapse (IS). The TCR and associated signaling 
molecules, including protein kinase C θ and 
CD28, are clustered at the center of the T 
cell–target cell contact, an area referred to as 
the central-supramolecular activation complex 
(c-SMAC) (2), whereas LFA-1 (also known as 
CD11a/CD18 or αL/β2 integrin), CD2, CD8, 
and talin are localized at a ring-shaped structure 
surrounding the c-SMAC, referred to as the 
peripheral-SMAC (p-SMAC) (3). p-SMAC, 
which is formed upon ligation of LFA-1 on 
CTLs by high densities of intercellular adhe-
sion molecule (ICAM)-1 on target cells, is es-
sential for directing released cytolytic granules 
to the surface of tumor cells near c-SMAC and 
eff  ective lysis of the latter cells by CTLs (4–6).
Most human lung cancers arise from the 
bronchial epithelium and belong to the   categories 
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Various T cell adhesion molecules and their cognate receptors on target cells promote T cell 
receptor (TCR)–mediated cell killing. In this report, we demonstrate that the interaction of 
epithelial cell marker E-cadherin with integrin 𝗂E(CD103)𝗃7, often expressed by tumor-
infi  ltrating lymphocytes (TILs), plays a major role in effective tumor cell lysis. Indeed, we 
found that although tumor-specifi  c CD103+ TIL-derived cytotoxic T lymphocyte (CTL) 
clones are able to kill E-cadherin+/intercellular adhesion molecule 1− autologous tumor 
cells, CD103− peripheral blood lymphocyte (PBL)-derived counterparts are ineffi  cient. This 
cell killing is abrogated after treatment of the TIL clones with a blocking anti-CD103 
monoclonal antibody or after targeting E-cadherin in the tumor using ribonucleic acid 
interference. Confocal microscopy analysis also demonstrated that 𝗂E𝗃7 is recruited at the 
immunological synapse and that its interaction with E-cadherin is required for cytolytic 
granule polarization and subsequent exocytosis. Moreover, we report that the CD103− 
profi  le, frequently observed in PBL-derived CTL clones and associated with poor cytotoxicity 
against the cognate tumor, is up-regulated upon TCR engagement and transforming 
growth factor 𝗃1 treatment, resulting in strong potentiation of antitumor lytic function. 
Thus, CD8+/CD103+ tumor-reactive T lymphocytes infi  ltrating epithelial tumors most likely 
play a major role in antitumor cytotoxic response through 𝗂E𝗃7–E-cadherin interactions.
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of non-small cell lung carcinoma (NSCLCs), including adeno-
carcinomas (ADCs), large cell carcinomas (LCCs), and squa-
mous cell carcinomas (SCCs). During cancer cell dissemination, 
NSCLCs frequently display reduced or absent MHC-I expres-
sion, which is often accompanied by loss of ICAM-1 (7). These 
tumors are often infi  ltrated by TCR-α/β+, CD8+, and CD28− 
T lymphocytes, and tumor-specifi  c CTLs with high functional 
avidity were found to be selectively expanded at the tumor site, 
suggesting that they may contribute to control of the tumor 
(8). We previously isolated, from lymphocytes infi  ltrating an 
MHC-Ilow/ICAM-I− LCC and autologous PBL, two tumor-
specifi  c T cell clones expressing a unique TCR and displaying 
a CD8+/CD28−/CD27−/CD45RA+/CD62L−/CCR7− ter-
minally diff  erentiated eff  ector phenotype (9). Although both 
clones exhibited identical functional avidity and similar lytic 
potential, as measured by granzyme B and perforin intracellular 
expression and redirected cell killing, only the tumor-  infi  ltrating 
lymphocyte (TIL)-derived clone mediated potent cytolytic 
  activity toward autologous tumor cells (9). To gain further 
  insight into molecular mechanisms underlying diff  erential anti-
tumor T cell reactivity, we conducted comprehensive micro-
array analysis using an Agilent oligonucleotide array. Functional 
studies indicated that the selective expression of integrin 
αE(CD103)β7 by the TIL-derived clone was crucial for 
directional cytotoxic granule exocytosis in the ICAM-1−/
E-cadherin+ tumor leading to cell death.
RESULTS
CD103 is differentially expressed in tumor-specifi  c 
TIL- and PBL-derived T cell clones
Using mutated α-actinin-4 peptide–HLA-A2 tetramers, we 
isolated, from the PBLs and TILs of a lung cancer patient, 
Figure 1.  Surface expression of 𝗂E𝗃7 integrin on tumor-infi  ltrating 
and peripheral blood T cells. (A) Expression of αEβ7, LFA-1, CD2, and 
TCR-α/β on Heu171 and H32-22 T cell clones. Immunofl  uorescence analysis 
was performed using anti-CD103, anti-CD11a, anti-CD2, and anti-TCRVβ8 
(fi  lled) mAbs or isotypic control (open). (B) Detection of CD103+ T cells in 
uncultured TILs and PBLs. Two-color fl  ow cytometry analysis was performed 
using FITC-conjugated anti-CD103 and PE-conjugated anti-CD3 mAbs. 
Three uncultured NSCLC patient TIL and PBL samples and three healthy 
donor (HD) PBL samples are shown. Percentages of positive cells are indicated. 
Numbers in parentheses correspond to mean fl  uorescence intensities.JEM VOL. 204, March 19, 2007  561
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two tumor-specifi  c T cell clones named H32-22 and Heu171, 
respectively. Although both clones expressed a unique TCR 
and displayed similar lytic potential, only the TIL clone, 
Heu171, elicited strong cytolytic activity toward the autolo-
gous IGR-Heu tumor cell line (9). To gain further insight 
into the molecular mechanisms underlying the diff  erential 
functional activity of TIL and PBL clones, we compared their 
transcriptional profi  les by microarray analysis using an Agi-
lent 44000 human oligonucleotide array. Global gene ex-
pression studies performed with a p-value of ≤10−5 identifi  ed 
an expression profi  le of 491 genes, including a cluster of 241 
genes that were less strongly expressed in TILs than PBLs, 
and a cluster of 250 genes that were more strongly expressed 
in the TIL than PBL clone (Fig. S1 A, available at http://
www.jem.org/cgi/content/full/jem.20061524/DC1). Re-
sults acquired with a fold change of ≥2 identifi  ed an expres-
sion profi  le of 148 genes, including clusters of genes related 
to adhesion/recognition, cell death, locomotion/localization, 
metabolism, physiological processes, regulation, and response 
to stimulus (Fig. S1 B and Table S1, available at http://www
.jem.org/cgi/content/full/jem.20061524/DC1). Among 
the adhesion/recognition genes, ITGAE, encoding the αE 
(CD103) subunit of the αEβ7 integrin, was one of the most 
overexpressed genes in the TIL clone, with a sixfold stronger 
expression in the TIL than in the PBL clone, which was con-
fi  rmed both by quantitative PCR analyses (unpublished data) 
and at the protein level (see below; Fig. 1 A). Moreover, such 
a stronger expression was consistently observed in several 
  microarray analyses performed with additional TIL clones 
(Heu127 and Heu161; references 10 and 11, respectively) and 
a PBL cell line (H32; reference 9) derived against IGR-Heu 
(Table S2), making αE (CD103) one of the best candidate 
molecules to be analyzed further.
We then assessed the expression of the αEβ7 protein on 
Heu171 and H32-22 by immunofl  uorescence analysis using 
an anti–human CD103 mAb (12). Results depicted in Fig. 1 A 
confi  rmed that αEβ7 was selectively expressed on the TIL 
clone. In contrast, both clones expressed similar levels of 
LFA-1 (CD11a/CD18), CD2, and TCR-α/β molecules 
(Fig. 1 A). NKG2D, CD8, CD44, and VCAM-1 were also 
expressed at similar levels by both clones (unpublished data), 
and CD5 was expressed at higher levels on PBLs than on 
TILs (9). CD31 (PECAM-1) was weakly expressed on only 
29% of Heu171 cells, and CD40L was not expressed on both 
clones (unpublished data). It is worth noting that αEβ7 is 
widely expressed on most autologous and allogeneic CD8+ 
tumor-specifi  c TIL clones tested, and at a lower level on two 
autologous tetramer+/CD8+ PBL clones (H32-8 and H32-25; 
Table I and unpublished data). Importantly, 17–33% of un-
cultured CD3+ TILs collected from eight NSCLC biopsies 
were found to express the integrin (Fig. 1 B and Table I). 
In contrast, only 1–2% and 2–6% of patient and healthy 
donor circulating T cells expressed CD103, respectively. These 
results indicate that αEβ7 is preferentially expressed by TILs 
and suggest that it may be induced upon T cell migration to 
the tumor site.
The 𝗂E𝗃7 integrin promotes TIL-mediated lysis 
of E-cadherin–expressing tumor cells
To determine the potential role of the αEβ7 integrin in TIL-
mediated tumor cell lysis, we performed cytotoxic experi-
ments in the absence or presence of anti-CD103–neutralizing 
mAb. Results indicate that Heu171 cells mediated strong cy-
totoxic activity toward IGR-Heu, which was abrogated in 
the presence of anti-CD103 ascite or purifi  ed mAb (Fig. 2 A 
and unpublished data). In contrast, a less dramatic inhibition 
was observed with anti–TCR-α/β and anti-CD8 mAb (un-
published data), and no inhibition was observed with anti-
CD2 and anti-CD3 mAb (Fig. 2 A). It is noteworthy that 
anti-CD103 mAb also blocked the cytotoxicity of all specifi  c 
TIL-derived clones against the autologous IGR-Heu target, 
and anti–LFA-1 mAb had no eff  ect because IGR-Heu failed 
to express ICAM-1 (unpublished data). With regard to PBL 
clones, H32-22 mediated a weak cytotoxic activity toward 
Figure 2.  Role of adhesion/costimulatory molecules in T cell 
clone–mediated cytotoxicity. (A) Role of CD103 in Heu171 TIL clone–
mediated lysis toward autologous IGR-Heu tumor cells. Cytotoxicity was 
determined by a conventional 4-h 51Cr-release assay at a 20:1 E/T ratio. 
Experiments were performed either in medium or in the presence of indi-
cated mAb. The Heu171 and H32-22 T cell clones were preincubated for 
1 h with saturating concentrations of anti-CD3, anti-CD2, anti-CD103, or 
a control mAb. (B) Role of LFA-1 in Heu171 and H32-22 clone–mediated 
lysis against peptide-pulsed autologous EBV-transformed B cell line. 
Cytotoxicity was determined by a conventional 4-h 51Cr-release assay 
at a 20:1 E/T ratio. The Heu-EBV B cell line was preincubated with 
 mutated  α-actinin-4 peptide. Experiments were performed either in me-
dium or after preincubating effector cells with anti-CD103, anti–LFA-1, 
or anti-CD8 mAbs. 562  αEβ7-E–CADHERIN INTERACTION PROMOTES CTL ACTIVITY | Le Floc’h et al.
Table I.  CD103 distribution among TIL and PBL T cell clones and uncultured TILs and PBLs
T cell phenotype % of CD3+/CD103+  MFI References
TIL-derived T cell clones
Patient 1 (Heu)
Heu171 CD8 97 428 9
Heu127 CD8 100 785 10
Heu161 CD8 99 452 11, 59
Patient 2 (Bla)
B90 CD8 100 677 19
B112 CD8 99 658 19
Patient 3 (Coco)
CTL-C1 CD8 14 46
Patient 4 (Pub)
P62 CD4 1 19
PBL-derived T cells 
Patient 1 T cell clones
H32-22 CD8 5 9
H23018 CD8 6 9
H32-8 CD8 96 126 9
H32-25 CD8 94 146 9
Patient 1 T cell line
H32 CD8 2 9
Uncultured T cells
TIL
Patient 5 33 274
Patient 6 25 96
Patient 7 27 135
Patient 8 17 299
Patient 9 22 300
Patient 10 22 374
Patient 11 23 115
Patient 12 22 93
Mean 23.7 ± 4.7 211
Patient PBL
Patient 1 (Heu) 1 104
Patient 5 2 176
Patient 6 17 4
Patient 7 11 0 5
Patient 13 2 146
Patient 14 29 7
Patient 15 1 149
Patient 16 1 188
Mean 1.3 ± 0.5 130
Healthy PBL
Healthy donor 1 6 102
Healthy donor 2 2 106
Healthy donor 3 2 96
Healthy donor 4 4 111
Healthy donor 5 4 123
Healthy donor 6 4 114
Healthy donor 7 3 90
Healthy donor 8 2 89
Mean 3.2 ± 1.6 104
Mean percentage of CD3+/CD103+ cells was signifi  cantly higher in TILs than in patient PBLs (P < 0.01) and healthy donor PBLs (P < 0.01). Statistical analyses were performed 
using the Mann-Whitney test. MFI, CD103 mean fl  uorescence intensity.
the cognate tumor that was unaff  ected by all neutralizing 
mAbs used (Fig. 2 A). Importantly, H32-8 and H32-25 dis-
played a specifi  c lysis that correlated with signifi  cant αEβ7 
expression and was inhibited by anti-CD103 mAb (Table II). 
Furthermore, Heu171 and H32-22 clones killed the autol-
ogous EBV-transformed B cell line pulsed with the antigenic 
peptide, and this lysis was inhibited by anti–LFA-1 (anti-
CD11a), but not by anti-CD103 mAb (Fig. 2 B),   emphasizing JEM VOL. 204, March 19, 2007  563
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the role of LFA-1–ICAM-1 adhesion in this particular 
T cell–target cell interaction and ruling out a nonspecifi  c 
effect of anti-CD103 ascite. These data strongly suggest 
that αEβ7 plays a major role in T cell–mediated   tumor 
cell killing.
Thus far, the only reported ligand of the αEβ7 integrin is 
E-cadherin (CD324), which is expressed by normal epithelial 
cells but which is frequently down-regulated in metastatic 
cancer cells (13). To assess whether the cytotoxicity blocking 
eff  ect of anti-CD103 mAb was due to inhibition of the αEβ7 
interaction with E-cadherin, we tested E-cadherin expression 
on IGR-Heu and investigated its potential implication in 
TIL-mediated lysis. Fig. 3 A indicates that tumor cells dis-
played a high level of E-cadherin but a very low level of 
ICAM-1 (CD54) and moderate expression of LFA-3 (CD58) 
and HLA-A2 molecules. We then inhibited E-cadherin ex-
pression in IGR-Heu using specifi  c small interfering RNA 
(siRNA; siRNA-E1 and siRNA-E2) and assessed target cell 
sensitivity to the Heu171 clone. Results depicted in Fig. 3 B 
indicate that siRNA-E1 and siRNA-E2 dramatically blocked 
E-cadherin expression in tumor cells, resulting in abrogation 
of TIL-mediated killing (Fig. 3 C). In contrast, luciferase 
siRNA (siRNA-Luc), used as a control, had no eff  ect. It should 
be noted that E-cadherin knockdown did not aff  ect tumor 
cell sensitivity to healthy donor NK cell–mediated lysis, ex-
cluding an eff  ect on target cell susceptibility to apoptosis (un-
published data). In addition, transfection of the EBV-B cell 
line with siRNA-E1 and siRNA-E2 followed by loading 
with antigenic peptide did not alter T cell clone–mediated 
Figure 3.  Down-regulation of E-cadherin expression on IGR-Heu 
results in inhibition of Heu171 cytotoxicity against its specifi  c target. 
(A) Analysis of surface expression of E-cadherin (CD324), ICAM-1 (CD54), 
LFA-3 (CD58), and HLA-A2.1 on IGR-Heu tumor cells. Immunofl  uorescence 
analysis was performed using anti–E-cadherin, anti-CD54, anti-CD58, anti–
HLA-A2.1 (fi  lled) mAbs or an isotypic control (open). Percentages of positive 
cells are indicated. Numbers in parentheses correspond to mean fl  uorescence 
intensities. (B) Analysis of E-cadherin surface expression on IGR-Heu tumor 
cells electroporated or not with siRNA targeting E-cadherin, siRNA-E1, 
and siRNA-E2. Luciferase siRNA (siRNA-Luc) was used as a control. 
(C) Effect of E-cadherin extinction on tumor cell killing by the Heu171 TIL 
clone. Cytotoxicity was determined by a conventional 4-h 51Cr-release assay 
at the indicated E/T ratios. IGR-Heu tumor cells electroporated or not with 
siRNA-E1, siRNA-E2, or siRNA-Luc were used as targets.
Table II.  CD103 levels refl  ect T cell clone antitumor 
cytolytic activity
CD103 expression % of lysis
% MFI Medium Anti-CD103
PBL
H32-22 3a 9b 7
H32-8 85 81 32 6
H32-25 72 119 49 21
TIL
Heu171 95 293 60 8
Immunofl  uorescence and cytotoxic activity of T cell clones. Data shown are 
representative of three independent experiments.
aPercentages of CD103+ T cells and mean fl  uorescence intensities (MFIs) are indicated.
bCytotoxicity toward autologous IGR-Heu tumor cell line was determined by a 
conventional 4 h 51Cr-release assay at a 20:1 E/T cell ratio.564  αEβ7-E–CADHERIN INTERACTION PROMOTES CTL ACTIVITY | Le Floc’h et al.
cytotoxicity (unpublished data). These data further support 
the notion that the αEβ7–E-cadherin interaction is crucial for 
eff  ective cancer cell lysis; moreover, they suggest that it may 
substitute LFA-1–ICAM-1 adhesion in the promotion of TCR-
mediated tumor cell killing.
TGF-𝗃1–induced expression of CD103 potentiates PBL 
clone–mediated tumor cell killing
The above experiments clearly indicated that CD103 was 
widely expressed on CD8+ T cells infi  ltrating NSCLC and 
suggested that it may be induced upon migration of anti  gen-
specifi  c T lymphocytes within the tumor. One factor abun-
dantly secreted by neoplastic cells including IGR-Heu 
NSCLC (14 and unpublished data) is TGF-β1, known for 
its immunosuppressive eff  ects but also for its capacity to 
  induce CD103 expression upon T cell activation (15). We 
therefore assessed the eff  ect of TGF-β1, associated or not 
with coated anti-CD3 mAb, on the expression of CD103 on 
the H32-22 clone. Immunofl  uorescence analyses revealed 
that TGF-β1 induced a sharp increase in CD103 expression 
on a subset of the H32-22 clone when combined with anti-
CD3 mAb (Fig. 4 A). In contrast, TGF-β1 alone had only a 
slight eff  ect on CD103 expression, and anti-CD3 alone had 
no eff  ect.
Next, we performed cytotoxicity assays with H32-22, 
pretreated with coated anti-CD3, TGF-β1, or a combination 
of both, in the absence and presence of anti-CD103 mAb. 
The Heu171 TIL clone was included as a positive control. 
Data depicted in Fig. 4 B indicate that anti-CD3 mAb alone 
had no eff  ect on H32-22 cytolytic activity toward autologous 
tumor cells, excluding its contribution to putative redirected 
target cell lysis. Interestingly, treatment of the PBL clone 
with a combination of anti-CD3 and TGF-β1 resulted in a 
strong increase in its cytotoxicity toward IGR-Heu. Such 
potentiation is dependent on αEβ7 induction because anti-
CD103 mAb completely inhibited this killing (Fig. 4 B). 
TGF-β1 alone induced only a partial increase in H32-22–
mediated lysis, which was signifi   cantly inhibited by anti-
CD103 mAb. These data further support a role for TGF-β1 
together with TCR engagement in the induction of CD103 
on tumor-specifi  c T lymphocytes upon their migration to 
the tumor microenvironment, and they point to the involve-
ment of this integrin in TCR-mediated epithelial cancer 
cell lysis.
Interaction of E-cadherin with 𝗂E𝗃7 is essential for granule 
polarization and exocytosis
Failure of the H32-22 PBL-derived clone to kill autologous 
tumor cells might indicate that the interaction of E-cadherin 
with integrin αEβ7 is required for directional exocytosis of 
cytolytic granules. To test this hypothesis, we fi  rst assessed 
whether αEβ7 was engaged in TIL–tumor cell IS. For this 
purpose, Heu171 cells were incubated with IGR-Heu, and 
conjugates were stained with anti-CD103 mAb at diff  erent 
time intervals. Confocal microscopy analyses indicate that 
Heu171 cells formed stable conjugates with IGR-Heu and that 
the αEβ7 integrin progressively accumulated within the IS (Fig. 
5 A). This was found in 91% of analyzed conjugates (n = 200). 
Next, to follow granule polarization and exocytosis, IGR-Heu 
cells were mixed with Heu171 or H32-22 cell clones, and 
Figure 4.  Role of TGF-𝗃1 in CD103 induction and potentiation of 
T cell clone–mediated lysis. (A) H32-22 T cells were cultured in medium 
or in the presence of TGF-β1, coated anti-CD3 mAb, or a combination of 
both for 96 h. CD103 expression was then assessed by immunofl  uores-
cence analysis. Percentages of positive cells are indicated. Numbers in 
parentheses correspond to mean fl  uorescence intensities. (B) Role of 
TGF-β1–induced expression of CD103 in potentiation of H32-22–mediated 
killing. Cytotoxicity was determined by a conventional 4-h 51Cr-release 
assay at a 20:1 E/T cell ratio. The H32-22 clone treated or not with TGF-
β1 and/or coated anti-CD3 mAb and the Heu171 clone used as a control 
were preincubated for 1 h with saturating concentrations of anti-CD103 
or a control mAb.JEM VOL. 204, March 19, 2007  565
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Figure 5.  Engagement of 𝗂E𝗃7 in TIL–tumor cell IS is essential for 
granule polarization and exocytosis. (A) Recruitment of αEβ7 integrin 
in the IS formed between the Heu171 TIL clone and the IGR-Heu tumor 
cell line. Confocal microscopy analysis of CD103 localization (green fl  uo-
rescence) in the contact area between the Heu171 and the IGR-Heu at the 
indicated time course. Nuclei were stained with TO-PRO-3 iodide (blue 
fl  uorescence). Bars, 5 μm. (B) On the left: TIL and PBL clones form stable 
conjugates with autologous tumor cells. Conjugates formed between 
the IGR-Heu and the H32-22 or Heu171 effector cells were analyzed by 
confocal microscopy after 15 min of co-culture. Granule polarization, as 
defi  ned by the accumulation of granzyme B in the contact area between 
effector and tumor cells, was followed up using anti–granzyme B mAb 
(green fl  uorescence). On the right: E-cadherin siRNA does not affect con-
jugate formation between TIL and the cognate target but inhibits granule 
polarization. IGR-Heu tumor cells were pretreated with siRNA targeting 
E-cadherin (siRNA-E1) or luciferase (siRNA-Luc). Conjugates formed with 
the Heu171 TIL were then analyzed. Nuclei were stained with TO-PRO-3 
iodide (blue fl  uorescence). Bars, 5 μm. (C) Percentages of CTLs displaying 
granzyme B relocalization during conjugate formation between the 
H32-22 and IGR-Heu or the Heu171 and IGR-Heu pretreated or not with 
siRNA-E1 or siRNA-Luc. Data shown represent mean ± SD of three inde-
pendent experiments. Numbers of conjugates analyzed are indicated in 
parentheses. (D) Effi  ciency of conjugate formation between IGR-Heu and 
effector T cells was calculated by determining the E/T ratio × 100 as 
described in Materials and methods. Data represent the mean ± SD of 
quadruplicate fi  elds including  140 tumor cells each. (E) CD107a induc-
tion on Heu171 cells during co-culture with the IGR-Heu pretreated or 
not with siRNA targeting E-cadherin or luciferase, and on H32-22 stimu-
lated or not with a combination of TGF-β1 and coated anti-CD3 mAb, 
during co-culture with IGR-Heu tumor cells. Immunofl  uorescence analysis 
was performed at the indicated time course. Staining with anti–human 
CD8 mAb was included to identify T lymphocytes.566  αEβ7-E–CADHERIN INTERACTION PROMOTES CTL ACTIVITY | Le Floc’h et al.
  polarization of cytotoxic granules, as defi  ned by granzyme B 
accumulation in the contact area between eff  ector and tumor 
cells, was analyzed by confocal microscopy. Data shown in Fig. 
5 B indicate that polarization of cytotoxic granules occurred 
in the TIL-derived clone only, and delivery of Alexa-labeled 
granzyme B into target cells was even detected in most of con-
jugates analyzed. Granzyme B polarization was observed in 
84 ± 7% of conjugates formed between Heu171 and IGR-
Heu (n = 310), but only in 11 ± 2% of conjugates formed 
between H32-22 and tumor cells (n = 306) (Fig. 5 C). Im-
portantly, silencing of E-cadherin with siRNA-E1 did not 
  alter formation of conjugates between Heu171 and IGR-Heu 
(Fig. 5 D), but resulted in strong inhibition of cytotoxic gran-
ule polarization because only 15 ± 3% of conjugates (n = 
293) displayed polarized granzyme B–containing granules 
(Fig. 5, B and C). In contrast, control siRNA (siRNA-Luc) 
had no eff  ect on cytotoxic granule polarization because 82 ± 
7% of the analyzed conjugates (n = 270) exhibited granzyme 
B relocalization.
Cytolytic granules are secretory lysosomes with a dense 
core containing perforin and granzymes surrounded by a lipid 
bilayer that contains lysosomal-associated membrane glyco-
proteins and FasL (16–18). Degranulation by CTLs results 
in CD107a (lysosomal-associated membrane glycoprotein 1) 
externalization at the cell surface and release of intracellular 
perforin and granzyme B. Therefore, we also assessed the 
role of the αEβ7 interaction with E-cadherin in granule exo-
cytosis by monitoring CD107a levels in Heu171 and H32-
22 cells. Immunofl  uorescence analysis indicated that CD107a 
was induced only at the surface of Heu171 TILs and that 
pretreatment of target cells with siRNA targeting E-cadherin 
partially inhibited this process (Fig. 5 E). Interestingly, 
pretreatment of H32-22 with a combination of anti-CD3 
mAb and TGF-β1 followed by exposure to tumor cells 
strongly induced CD107a labeling to levels comparable to 
those observed on Heu171 (Fig. 5 E). These results empha-
size the essential role of the αEβ7–E-cadherin interaction in 
granule polarization and exocytosis by tumor-specifi  c TILs 
to kill their target.
Complementary role of 𝗂E𝗃7–E-cadherin and 
LFA-1–ICAM-1 interactions in TIL-mediated lysis
Our previous results clearly demonstrated a major role 
for αEβ7 in TCR-mediated killing of tumor-reactive CTLs 
infi  ltrating an ICAM-1−/E-cadherin+ carcinoma. To inves-
tigate the engagement of αEβ7–E-cadherin in a combination 
in which LFA-1–ICAM-1 adhesion is eff  ective, we used 
NSCLC tumor cell line LCC-B2, expressing both ICAM-1 
and E-cadherin (Table III), and a specifi  c CD8+/CD103+ 
CTL clone, B90, isolated from autologous TILs (Table I; 
reference 19). B90 cells were mixed with LCC-B2 and 
  conjugates stained with either anti–LFA-1 or anti–CD103 
mAb. Confocal microscopy analyses of n = 100 conjugates 
indicated that both LFA-1 and αEβ7 integrins accumulated 
within the IS of 91 and 81% of TIL–tumor cell conjugates, 
respectively (Fig. 6 A).
Next, we assessed the eff  ect of anti-CD103 and anti–LFA-
1 mAb on CTL clone–mediated lysis toward the LCC-B2 
autologous target. Results indicated that although each mAb 
had only a weak inhibitory eff  ect on T cell clone–  mediated 
killing, a combination of the two mAbs strongly blocked 
tumor cell lysis (Fig. 6 B). Of note, treatment of IGR-Heu with 
IFN-γ induced ICAM-1 expression and MHC-I molecule 
up-regulation resulting in an increase in H32-22–mediated 
lysis, which was partially inhibited by anti–LFA-1 but not 
by anti-CD103 mAb ( unpublished data). In contrast, stable 
transfection of IGR-Heu with ICAM-1 had only a marginal 
eff  ect on H32-22–mediated lysis (unpublished data), support-
ing our recent report emphasizing an inhibitory role of CD5 
when the strength of the TCR/peptide–MHC interaction is 
weak (9). These results further emphasize a role for CD103 
in TIL-mediated tumor cell killing and suggest that ICAM-1 
and E-cadherin display complementary roles in T cell–tumor 
cell cytotoxic IS maturation.
Figure 6.  Both LFA-1 and 𝗂E𝗃7 integrins are engaged in TIL–tumor 
cell IS. (A) Confocal microscopy analysis of CD103 and LFA-1 localization 
(green fl  uorescence) in conjugates formed between the B90 TIL clone and 
the IGR-B2 autologous tumor cell line after 20 min of co-culture. Nuclei 
were stained with TO-PRO-3 iodide (blue fl  uorescence). Bars, 5 μm. (B) Role 
of LFA-1 and αEβ7 integrins in TIL-mediated lysis of the ICAM-1+/
E- cadherin+ autologous tumor. Cytotoxicity was determined by a conven-
tional 4-h 51Cr-release assay at a 20:1 E/T ratio. The B90 TIL clone was 
  preincubated or not for 1 h with saturating concentrations of anti–LFA-1, 
anti-CD103, a combination of anti–LFA-1 and anti-CD103, or a control mAb.JEM VOL. 204, March 19, 2007  567
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DISCUSSION
Adhesion between CTLs and specifi  c target cells is thought 
to be a prerequisite for eff   ective TCR recognition and 
subsequent cytotoxicity. This adhesion is often provided 
by the interaction of LFA-1 on T cells with ICAM-1 on 
APCs. The role of the most enigmatic integrin, αEβ7 (20), 
in CTL-mediated killing and antitumor immune response 
remains poorly understood. The αEβ7 integrin is expressed 
at high levels by mucosal T cells, in particular intestinal epi-
thelium lymphocytes (21). It is also found on mucosal mast 
cells and DCs (22), CD4+/CD25+ T regulatory cells (23, 
24), and on a large proportion of CD8+ T cells infi  ltrating 
epithelial tumors, including bladder (25), colorectal (26), 
pancreatic (27), and lung carcinomas (this study). With re-
gard to PBLs, we found that only a small subset of NSCLC 
patient and healthy donor CD8+ T cells expressed the in-
tegrin. Our data also indicate that the expression level of 
αEβ7 on tumor-specifi  c T cell clones correlated with their 
capacity to kill autologous ICAM-1−/E-cadherin+ tumor 
cells. This killing was abrogated by anti-CD103–neutral-
izing mAb and siRNA-targeting E-cadherin, pointing to 
a major role for the αEβ7–E-cadherin interaction in anti-
tumor CTL response.
 It has been reported that the αE subunit can be induced 
by TGF-β1 upon T cell activation (28, 29). CD103 has been 
found on T cells residing in tissue microenvironments where 
this cytokine is abundant, such as in the vicinity of epithelia, 
in chronic infl  ammation (20), in renal allografts (15, 30, 31), 
and in epithelial tumors. Interestingly, incubation of the 
αEβ7
− PBL clone with a combination of coated anti-CD3 
mAb and TGF-β1 induced up-regulation of CD103 leading 
to potentiation of tumor-specifi  c cytotoxicity. The paradoxi-
cal role of this cytokine, often described as an immunosup-
pressive factor used by neoplastic cells to escape from the 
immune system, but also as an important mediator of tissue 
remodeling and repair at sites of infl  ammation (32), in the 
control of the antitumor immune response warrants further 
investigation. CD8+/CD103+ T cells were also described as 
playing a critical role in selective destruction of host intestinal 
epithelium during graft-versus-host disease (33) and pancre-
atic islet allografts (34), in mediation of tubular injury after 
allogeneic renal transplantation (35), and in anti-EBV CTL 
response in the tonsil (36), and TGF-β1 most likely acts as a 
regulating factor in CD103 expression. In a previous study, 
we clearly showed a correlation between intratumoral down-
regulation of the TCR inhibitory molecule CD5 and poten-
tiation of antitumor T cell reactivity (9). Our overall results 
suggest that upon migration to TGF-β1–rich tumor micro-
environment and TCR engagement, tumor-specifi  c T cells 
undergo an adaptation process to tumor peptide/MHC-I 
levels by modulating CD5 expression together with concom-
itant induction of CD103, resulting in optimization of TCR-
mediated cytotoxic activity.
Thus far, the only reported ligand of the αEβ7 integrin is 
E-cadherin (37–40). E-cadherin belongs to the type I family 
of cadherins, including E- (epithelial), N- (neuronal), P- (pla-
cental), M- (muscle), and R- (retinal) cadherins, and is ex-
pressed by epithelial cells forming homotypic bonds between 
adjacent cells. E-cadherin is known to possess a tumor sup-
pressor function (41), and reduced expression during cancer 
development and metastatic invasion has been observed in 
many epithelial tumors (42–46). Among the 16 lung tumor 
cell lines tested, 5 displayed high levels of E-cadherin, 4 dis-
played moderate expression, and 7 were negative (Table III). 
These results indicate that lung carcinomas frequently express 
reduced levels of E-cadherin and suggest that its extinction 
may be associated with tumor escape from the intraepithelial 
CTL response. Indeed, the heterophilic adhesive interaction 
between the E-cadherin and the αEβ7 integrin plays a pivotal 
role in retention of CD8+ T lymphocytes in epithelial tumors 
(20, 27), thus providing a local adaptive immune response 
(47). Furthermore, our results indicate that loss of E-cadherin 
expression, for example by specifi  c siRNA, abolishes TCR-
mediated tumor cell lysis by autologous CD8+/CD103+ 
CTLs. It is tempting to speculate that down-  regulation of 
E-cadherin by epithelial neoplastic cells during the in vivo 
metastatic process could induce a decrease or even the fail-
ure of tumor-specifi  c TILs to kill their target, suggesting a 
mechanism for immunological selection of cancer cells with 
reduced E-cadherin expression. It has been recently reported 
that E-cadherin is also a counterreceptor for one member of 
the C-type lectin-like receptor family, KLRG1 (48). Inter-
estingly, it has been demonstrated that E-cadherin binding of 
Table III.  E-cadherin, ICAM-1, and MHC-I molecule 
expression on NSCLC and SCLC cell lines
E-cadherin ICAM-1 MHC-I
NSCLC cell lines
LCC
IGR-Heu (patient 1) 100%a     (137) 12%         (14) 100%        (60)
IGR-B2 (patient 2) 45%        (146) 98%     (1619) 100%      (743)
LCC-M4 95%          (53) ND 99%          (43)
H1155 1% 27%         (35) 100%      (855)
H460 1% 88%       (159) 100%      (412)
ADC
ADC-Coco (patient 3) 1% 0% 1%
IGR-Pub (patient 4) 20%          (31) 99%       (486) 100%      (393)
ADC-Tor 3% 43%         (46) 100%      (807)
ADC-Let 3% ND 100%      (499)
A549 1% ND 7%            (36)
H1355 34%          (89) 0% 100%      (294)
SCC
SCC-Cher 93%          (93) ND 82%          (27)
Ludlu 92%          (64) 34%         (19) 100%      (360)
SK-Mes 2% 53%         (47) 100%      (105)
SCLC cell lines
DMS53 56%          (37) 46%         (43) 100%      (540)
DMS454 96%        (151) 58%         (25) 95%      (1198)
Numbers in parentheses correspond to mean fl  uorescence intensities. 
ND, not done.
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KLRG1 prevents lysis of E-cadherin–expressing targets by 
KLRG1+ NK cells (49). These results suggest that tumors 
lacking E-cadherin expression may be less sensitive to CTL-
mediated killing, but may become more susceptible to lysis 
by KLRG1+ NK cells. Of note, the TIL clones used in the 
present study failed to express KLRG1 (unpublished data).
Although TCR engagement is necessary for inducing 
the cytotoxic activity of CD8+ T lymphocytes, accessory 
molecules play a major role in mediating CTL degranula-
tion and eff  ective cytotoxicity (50–52). It has been reported 
that although the CD2–CD58 interaction is suffi   cient  to 
trigger CTL degranulation, LFA-1–ICAM-1 ligation is nec-
essary for eff  ective target cell lysis by the released granules 
(53, 54). Indeed, blocking of the LFA-1–ICAM-1 interac-
tion precludes pSMAC formation and leads to inhibition of 
specifi  c lysis without a detectable decrease in granule release 
(54). Our results indicate that in the absence of ICAM-1, 
often lost during tumor cell dissemination, E-cadherin plays 
a pivotal role in target cell lysis by the αEβ7
+ tumor-specifi  c 
TIL, most likely by promoting p-SMAC formation and sub-
sequent directional cytolytic granule exocytosis. The inter-
action of E-cadherin on tumor cells with αEβ7 on specifi  c 
TILs appears necessary for positioning of the cytotoxic gran-
ules near the interface and their release into the target. 
In the absence of both ICAM-1–LFA-1 and E-cadherin–αEβ7 
adhesion, recruitment of cytotoxic granules and their release 
and delivery into the target cell are precluded. Indeed, 
although the LFA-1+/αEβ7
− PBL clone formed stable con-
jugates with ICAM-1−/E-cadherin+ autologous tumor cells, 
it was unable to lyse its specifi  c target, most likely due to a 
defect in granule polarization and subsequent degranulation. 
This is further supported by experiments in which blocking 
of the αEβ7–E-cadherin interaction with siRNA targeting 
E-cadherin preserved TIL–tumor cell conjugate formation 
but precluded granule recruitment and release, as monitored 
by granzyme B relocalization and the expression of CD107a 
on the CTL surface. This result emphasizes the possibility 
that the interactions of TCR/peptide–MHC-I, likely in col-
laboration with CD8 and CD2-CD58, may not be suffi   cient 
to trigger CTL granule polarization. This may be associated 
with low expression levels of peptide–MHC-I and CD58 
molecules by tumor cells used in this study. Distinct roles 
of ICAM-1 and E-cadherin in epithelial tumor cell killing 
by specifi  c TILs are further supported by experiments per-
formed with ICAM-1+/E-cadherin+ tumor cells. Indeed, 
both adhesion molecules were recruited at the CTL–tumor 
cell IS, and additional inhibitory eff  ects of TIL-mediated lysis 
were observed using a combination of anti–LFA-1 and anti-
CD103 mAb.
Collectively, our results demonstrate a major role for 
  tumor-specifi  c CD8+/CD103+ CTLs infi  ltrating epithelial 
cancers in antitumor immune response. Our data also em-
phasize a key role for the αEβ7–E-cadherin interaction in 
promoting TIL–tumor cell cytotoxic IS maturation corre-
lated with granule polarization and directional exocytosis 
leading to an eff  ective tumor cell lysis. Future studies investi-
gating T cell–epithelial tumor cell conjugates, and in particu-
lar E-cadherin–αEβ7 and E-cadherin–KLRG1 interactions, 
will not only contribute to our understanding of the control 
of tumor progression, but may also provide novel targets for 
cancer immunotherapy.
MATERIALS AND METHODS
Derivation and culture of the tumor cell lines and T cell clones. The 
IGR-Heu tumor cell line was established from patient Heu suff  ering from LCC 
of the lung. Heu171, Heu127 (10), and Heu161 (11) T cell clones were isolated 
from autologous TILs. H32 T cell line and H32-22, H32-25, and H32-8 clones 
were isolated from autologous PBLs after stimulation with IGR-Heu and sort-
ing with peptide–MHC tetramers (9). The IGR-B2 cell line was derived from 
patient Bla LCC, and the B90 CTL clone was isolated from autologous TILs 
(19). The NSCLC cell lines ADC-Coco (55), IGR-Pub, LCC-M4 (19), SCC-
Cher, ADC-Tor, and ADC-Let were derived from tumor biopsies as described 
previously (9–11). A549 (ADC), SK-Mes, Ludlu (SCC), DMS53, and DMS454 
(SCLC) were purchased from the European Collection of Cell Cultures. H460, 
H1155 (LCC), and H1355 (ADC) were provided by S. Rogers (Brigham and 
Women’s Hospital, Boston, MA; reference 56). All tumor cell lines were main-
tained in culture as reported previously (10). The human experiments were 
  approved by the Institutional Review Board of the Gustave Roussy Institute.
Antibodies and fl  ow cytometry analysis. mAbs directed against CD103 
and CD8 and coupled to fl  uorescein and purifi  ed anti-CD103 mAb were pur-
chased from Immunotech. Anti-CD103 ascite was provided by N. Cerf-
  Bensussan (Hôpital Necker, Paris, France). Anti-CD107a coupled to 
CyChrome and anti-CD3 (UCHT1) mAb was provided by Becton Dickinson. 
Anti–E-cadherin mAb was purchased from R&D Systems, and anti–granzyme 
B mAb was from Caltag Laboratories. Anti–LFA-1, anti-CD2, anti–LFA-3, 
anti–ICAM-1, anti–HLA-A2.1 (MA2.1), anti-TCRVβ8, and anti-CD3 
(OKT3) mAbs were reported previously (19, 57).
Phenotypic analyses of T cells and tumor cells were performed by direct 
or indirect immunofl  uorescence using a FACSCalibur fl  ow cytometer. Data 
were processed using CELLQuest software (BD Biosciences). For CD103 
induction, T cells were pre-stimulated with a combination of coated anti-
CD3 mAb (UCHT1) and TGF-β1 (5 ng/ml; Abcys), and expression of 
CD103 was assessed at day 4. For granule exocytosis assay, IGR-Heu tumor 
cells were plated in fl  at-bottom 96-well plates. T cells were then added 
at diff  erent time points together with 3 μl anti-CD107a mAb at a 2:1 
E/T ratio. T cells were then stained using a mouse anti–human CD8 mAb.
Cytotoxicity assay. The cytotoxic activity of the T cell clones was measured 
by a conventional 4-h 51Cr-release assay using triplicate cultures. The au-
to  logous IGR-Heu tumor cell line and the autologous EBV-transformed B cell 
line (Heu-EBV), pulsed for 1 h at 37°C with 50 nM of the antigenic peptide, 
were used as targets in cytotoxicity experiments. E/T ratios were 30:1, 10:1, 
3:1, and 1:1, or 20:1. Supernatants were then transferred to LumaPlateTM-96 
wells (PerkinElmer), dried down, and counted on a Packard’s TopCount 
NXT. Percent-specifi  c cytotoxicity was calculated conventionally (58).
Oligo-microarray technology. Heu171 and H32-22 total RNA were 
directly compared using Agilent oligonucleotide dual color technology in 
running dye swap (duplicate experiments). Probe synthesis and labeling was 
performed by Agilent’s low fl  uorescent low input linear amplifi  cation kit. 
Hybridization was performed on human whole genome 44 k oligonucleo-
tide microarrays using reagents and protocols provided by the manufacturer. 
Feature extraction software provided by Agilent (version 7.5) was used 
to quantify the intensity of fl  uorescent images and to normalize results using 
the linear and lowest subtraction method. Primary analysis was performed 
using Resolver software (Rosetta Biosoftware). The microarray data related 
to this paper have been submitted to the Array Express data repository at the 
European Bioinformatics Institute (http://www.ebi.ac.uk/arrayexpress/) 
and are available under the access codes E-TABM-207 and E-TABM-208.JEM VOL. 204, March 19, 2007  569
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RNA interference. Gene silencing of E-cadherin expression by the IGR-
Heu cell line was performed using two sequence-specifi  c siRNAs, siRNA-
E1 (G  C  A  C  G  U  A  C  A  C  A  G  C  C  C  U  A  A  U  tt; no. 146381) and siRNA-E2 
(G  A  G  U  G  A  A  U  U  U  U  G  A  A  G  A  U  U  G  tt; no. 44988) purchased from Ambion. 
In brief, cells were transfected by electroporation with 0.8 nM siRNA in 
a gene Pulser Xcell electroporation system (Bio-Rad Laboratories) at 300 V, 
500  μF, using electroporation cuvettes (Eurogentec). A second electro-
poration was performed after 24 h, and cells were then cultured for 48 h. 
Luciferase siRNA, siRNA-Luc (siRNA duplex, C G  U  A  C  G  C  G  G  A  A  U  A  C  U-
U  C  G  A  dTdT, and U  C  G  A  A  G  U  A  U  U  C  C  G  C  G  U  A  C  G  dTdT), included as a 
negative control, was purchased from Sigma-Proligo.
Confocal microscopy. Tumor and eff  ector cells were plated on poly-l-
  lysine–coated coverslips (Sigma-Aldrich) at a 2:1 E/T ratio. Cells were then 
fi  xed with 4% paraformaldehyde for 1 h and permeabilized with 0.1% SDS or 
Triton X-100 for 10 min, followed by blocking with 10% FBS for 20 min. 
The fi  xed cells were stained with anti-CD103 or anti–LFA-1 mAb and then 
with a secondary mAb coupled to Alexa Fluor 488 (Invitrogen). All anti-
bodies were diluted in PBS containing 1 mg/ml BSA. Nuclei were stained 
with TO-PRO-3 iodide (Invitrogen). Coverslips were mounted with Vecta-
shield (Vector Laboratories) and analyzed using a fl  uorescence microscope 
(LSM-510; Carl Zeiss MicroImaging, Inc.) the next day. Z-projection of 
slices was performed using LSM Image Examiner software (Carl Zeiss Micro-
Imaging, Inc.). Polarization of cytotoxic granules was defi  ned by the accu-
mulation of granzyme B in the contact area between eff  ector and tumor cells. 
Effi   ciency of conjugate formation between CTLs and IGR-Heu cells was 
calculated by determining the ratio of eff  ector cells able to form conjugates 
with target cells to target cells × 100. In brief, 5 × 104 electroporated or not 
tumor cells were grown in Petri dishes for 48 h, and then 3 × 105 CTLs were 
added. After 20 min of co-culture, nonconjugated T cells were removed by 
gentle washing, and the remaining cells were fi   xed, permeabilized, and 
stained with Lysotracker Green (Invitrogen) for counting. Four confocal 
  microscopy fi  elds were analyzed for each condition, and SD were determined.
Online supplemental material. Fig. S1 illustrates global gene expression 
analysis in H32-22 and Heu171 T cell clones. Table S1 illustrates diff  er-
ential gene expression profi  les of H32-22 PBL and Heu171 TIL clones. 
Table S2 shows the combined analysis of diff  erential gene expression 
profi  les of Heu171, Heu127, or Heu161 TIL clones compared with H32 
PBL T cell line and Heu171 compared with H32-22 PBL clone. The 
online supplemental material is available at http://www.jem.org/cgi/content/
full/jem.20061524/DC1.
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